Q-omics provides the consensus-scored FBLN2 profile across patient tissues and cancer cell-line models. FBLN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBLN2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, FBLN2 protein abundance shows 22,402 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where FBLN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBLN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBLN2 survival associations across molecular data types. FBLN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBLN2 RNA expression–survival associations across cancer types. High FBLN2 expression shows unfavorable associations in KIRP, but favorable associations in KIRC, LIHC, ESCA, HNSC and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBLN2 RNA expression.
This table summarizes FBLN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBLN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBLN2 shows lower tumor expression in KICH, THCA, BLCA, COAD and BRCA and higher tumor expression in HNSC. The KICH box plot shows higher FBLN2 RNA expression in normal versus tumor tissue (log2 FC = −3.281, t-test p < 0.001).
This table shows molecular features associated with FBLN2 in patient tissues and cancer cell lines. In patient samples, FBLN2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBLN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
